MAPT and Alzheimer disease: Thus far we have mainly focused on Aβ; however, XMU-MP-1 may also be effective against tau pathology as demonstrated in an STZ-induced rat model of sporadic AD, where XMU-MP-1 administration protected against tau hyperphosphorylation, Aβ deposition, oxidative stress, acetylcholinesterase hyperactivity, neuroinflammation, loss of synaptic proteins, increased apoptosis, and neuronal loss and morphological changes [15].